News

May 25, 2018May 25, 2018

Trial Data Supports Darzalex Combo as Potentially Effective in Myeloma Patients Who Don’t Respond to Revlimid

News

A combination of Darzalex (daratumumab) plus Kyprolis (carfilzomib) and dexamethasone is well-tolerated and may be effective in multiple myeloma patients who fail to respond to treatment with Revlimid (lenalidomide), data from a Phase 1b ... Read more

May 23, 2018

Canadian Researchers Launch Study to Make Stem Cell Transplants Safer, More Efficient

News

Researchers in Canada are studying how to reduce the risks associated with the treatment of multiple myeloma by improving the safety and efficacy of stem cell transplants through the ... Read more

May 21, 2018

MS Therapy May Ease Painful Side Effect of Velcade Treatment in Myeloma Patients, Study Says

News

A multiple sclerosis (MS) treatment reduced a common painful side effect of Velcade (bortezomib) in a mouse model, suggesting that it might help myeloma patients complete their treatment and ... Read more

May 18, 2018May 18, 2018

Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018

News

Celgene’s investigational and second-generation CAR T-cell therapy bb2121 is showing real promise in treating advanced multiple myeloma patients, those with relapsed or refractory disease, updated Phase 1 data is ... Read more

May 16, 2018

Recruitment Open for Phase 2 Trial Aimed at Complete Eradication of Myeloma Cells

News

The University of Alabama at Birmingham (UAB) is recruiting patients with newly diagnosed multiple myeloma for a Phase 2 trial evaluating an innovative treatment approach with the goal of ... Read more

May 14, 2018

FDA Names Cancer Vaccine Galinpepimut-S Orphan Drug as Possible Multiple Myeloma Treatment

News

The investigational cancer vaccine galinpepimut-S (GPS) has been designated an orphan drug by the U.S. Food and Drug Administration as a possible treatment of multiple myeloma, Sellas Life Sciences ... Read more

May 11, 2018

FDA Approves Darzalex Combo Therapy for Certain Newly Diagnosed Patients

News

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with standard therapy for the treatment of patients with newly-diagnosed multiple myeloma who are not eligible for stem ... Read more

May 9, 2018May 10, 2018

Selinexor May Bring Hope to Heavily Treated Myeloma Patients, Trial Results Show

News

A quarter of heavily treated patients with penta-refractory multiple myeloma responded to Karyopharm‘s investigative oral therapy selinexor (KPT-330), according to top-line data from a Phase 2 study. The results bring ... Read more

May 7, 2018

9/11 Firefighters at Greater Risk of Multiple Myeloma Precursor, Study Reports

News

New York City firefighters exposed to the 9/11 World Trade Center (WTC) disaster are at greater risk for developing a condition called monoclonal gammopathy of undetermined significance (MGUS), which may ... Read more

May 4, 2018May 4, 2018

Stand Up to Cancer Awards $10 Million to ‘Dream Team’ Focused on Early Detection of Precursor Multiple Myeloma Conditions

News

Stand Up to Cancer (SU2C) recently awarded $10 million to a SU2C Dream Team that wants to move the treatment of multiple myeloma from a “watch and wait” approach ... Read more